Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Using three-dimensional tumor models and a next-generation technology platform, MEDiC Life Sciences aims to break boundaries in cancer drug development.
While external factors have put a dampener on acquisitions of oncology companies in the past year, the search for next-generation therapeutics from innovative platforms has driven dealmaking.
Pelago Bioscience, founded in 2013, aims to improve human health by helping its partners to discover and develop better therapeutics for difficult-to-drug targets.
Genialis has created ResponderID, a machine-learning platform that unravels complex biological signatures from patient data to deliver next-generation biomarkers for diagnostic and drug development.
The development of antibodies and associated technologies continues to drive high-value deals. We look at recent trends in the field with help from DealForma.
With three decades of experience, over 200 client partnerships and several cell-line development platforms, Aragen Bioscience supports its global biopharma clients with end-to-end biologics development solutions and services.
GV20 Therapeutics’ platform decodes patients’ B cell responses with artificial intelligence to discover novel targets and antibodies simultaneously. Targets and antibodies are validated and de-risked computationally and experimentally.
The Korea Drug Development Fund and its ADCaptain Project are helping to bring novel antibody therapeutics through the development pipeline to patients in need.
Xentria is taking an innovative approach leveraging in vitro and pharmacokinetic models and the power of partnerships to co-develop accessible treatment options for patients with unmet needs.
Bioengineered Probiotic Yeast Medicines are oral, live therapeutics that express and secrete disease-targeting therapeutic molecules in situ for the treatment of gastrointestinal-related diseases. This synthetic biology approach offers advantages over conventional protein biologics and fulfils the dream of oral administration.
Perspix Biotech’s roPROTix platform combines artificial intelligence, robotics, and wet biology in a closed-loop feedback system for the discovery of next-generation multi-targeting biological therapeutics.
Captor Therapeutics is building a singular pipeline of both next-generation bifunctional degraders and molecular glues based on novel E3 ligases, leveraging academic expertise and industry experience in the United States and Europe, while utilizing significant public and private investment.
South Korean biotech Prazer Therapeutics is creating and validating a breakthrough drug discovery and development platform based on targeted protein degradation (TPD) technology to tackle previously undruggable targets in oncology, neuroscience and other therapeutic areas that are not readily addressable with existing TPD approaches.
InduPro is mapping the cell-surface proteome and designing novel binding proteins to bring cell-surface proteins together to manipulate signaling biology across a range of disease-relevant contexts.
By leveraging the body’s natural RNA-delivery pathways, Sixfold Bioscience is developing a platform that uses modified RNA tags to deliver RNA therapies to desired cell types.
